Medication for hearing loss after fractionated stereotactic radiotherapy (SRT) for vestibular schwannoma.
OBJECTIVE
To investigate the effectiveness of corticosteroid treatments for patients showing decreases in hearing levels after stereotactic radiotherapy for vestibular schwannoma.


METHODS
Twenty-one patients experienced a hearing loss in pure-tone average at greater than 20 dB or less than 10 dB within 1 year after irradiation administration of 44 Gy/22 fractions followed by a 4 Gy boost. Eight received oral prednisone at a daily dose of 30 mg, which was gradually decreased (medicated group), and 13 received none (nonmedicated group). The average observation period was 26.7 +/- 16.6 (range: 6--69) months.


RESULTS
Hearing recovery was seen after initial onset of the hearing loss in all 8 patients in the medicated group and in 2 of 13 patients in the nonmedicated group (p = 0.001). The hearing recovery, that is, the change in pure-tone average (dB) at the last follow-up from the onset of hearing loss, was 9.8 +/- 6.9 dB (recovery) in the medicated group and -9.4 +/- 12.8 dB (further loss) in the nonmedicated group (p = 0.0013). The hearing recovery rate, normalizing to the degree of the hearing loss before medication, was also significantly higher in the medicated group than in the nonmedicated group (p = 0.0014).


CONCLUSIONS
Corticosteroidal intake is suggested to be effective in improving hearing loss after stereotactic radiotherapy, at least in young patients having a useful pretreatment hearing level, if the treatment for hearing loss is administered immediately after the hearing loss is first detected.
Sakamoto
T
T
Department of Otolaryngology, Hokkaido University School of Medicine, Sapporo, Japan.
Shirato
H
H
Takeichi
N
N
Aoyama
H
H
Kagei
K
K
Nishioka
T
T
Fukuda
S
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001301:Audiometry, Pure-Tone; D019583:Dose Fractionation, Radiation; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009464:Neuroma, Acoustic / Q000150:complications / Q000601:surgery*; D011241:Prednisone / Q000627:therapeutic use*; D011832:Radiation Injuries / Q000188:drug therapy* / Q000209:etiology; D016634:Radiosurgery / Q000009:adverse effects*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014725:Vestibular Nerve / Q000528:radiation effects* / Q000601:surgery
D000893:Anti-Inflammatory Agents; D011241:Prednisone